Beroni Group
Beroni Group is a publicly listed Australian biopharmaceutical company operating across Australia, China, Japan, and the USA. It develops cell therapies, anti-cancer drugs (including PENAO), infectious disease diagnostics, consumer probiotics, and an AI drug R&D model, serving hospitals, consumers, and pharma partners.
- Company typePublic
- Founded2014
- HeadquartersSydney, Australia
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Beroni Group does
Beroni Group is a publicly listed international biopharmaceutical company (NSX: BTG; OTCQX: BNIGF), founded in 2014 and headquartered in Sydney, Australia, with operating subsidiaries in China, Japan, and the United States. The company operates four core businesses: cell therapies (Gamma Delta T-cells, DC-CIK immunotherapy, NK/NKT therapies), anti-cancer drug development (led by the PENAO asset licensed/collaborated with the University of New South Wales, which is in Phase II clinical trials), infectious disease diagnostics (CE-certified and FDA Emergency Use Authorized SARS-CoV-2 antibody and antigen test kits, plus the CII-ArboViroPlex multiplex rRT-PCR assay under exclusive license from Columbia University), and a consumer e-commerce platform for pharmaceutical and healthcare products anchored by the Beilemei (倍乐美) probiotics brand in China.
The company's underlying technology portfolio includes proprietary nucleic acid aptamers (Aptamer-Wu, APT-Tan, APT8) with four filed Chinese invention patents for liver cirrhosis treatment, an independent Lipid Nanoparticle (LNP) delivery formulation technology for nucleic acid drugs, an AI-based drug R&D model developed in collaboration with Tsinghua University School of Software, and an iNKT cell anti-tumor therapy platform using AAV adjuvant strategy and pancreatic cancer-tropic capsids. Manufacturing infrastructure includes an AABB-standard Cell Preparation Center in Zhuhai with four cell preparation and exosome product lines.
Beroni generates revenue through pharmaceutical product sales (direct and e-commerce), drug commercialization (anti-cancer and diagnostic products), R&D and nucleic acid drug CRO services for partners, and diagnostic kit sales. The consumer Beilemei probiotic product retails at approximately 200 yuan (~$30 USD) per bag. Customer segments span healthcare providers (hospitals conducting clinical trials and purchasing diagnostics), consumers (e-commerce health product buyers), pharmaceutical/biotech partners (CRO services and co-development), and clinical laboratories. The company employs 51–100 corporate staff supplemented by a network of over 200 research scientists across its global operations, and is led by Founder, Chairman and CEO Jacky Zhang with Hai Huang as Group COO and Peter Wong as CFO.
Beroni Group firmographics
Firmographics- Name
- Beroni Group
- Legal name
- Beroni Group Limited
- Website
- https://beronigroup.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Beroni Group is a publicly listed Australian biopharmaceutical company operating across Australia, China, Japan, and the USA. It develops cell therapies, anti-cancer drugs (including PENAO), infectious disease diagnostics, consumer probiotics, and an AI drug R&D model, serving hospitals, consumers, and pharma partners.
- Ownership category
- akta.pro rank
Beroni Group industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industries
- Probiotics & Digestive Health Supplements (CRADAGAF), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where Beroni Group is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices7 records
Markets served
Beroni Group business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Sale of pharmaceutical and healthcare products through e-commerce platform and direct sales channels
- Drug Commercialization: Commercialization of developed drugs including anti-cancer treatments and infectious disease diagnostics
- R&D Services: Research and development services including nucleic acid drug CRO services for partners
- Diagnostic Products: Sale of diagnostic kits for infectious diseases including COVID-19 antigen and antibody detection kits
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Beilemei probiotics health product |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Beroni Group product offering
Product offeringCore offering
Beroni Group develops, manufactures, and commercializes biopharmaceutical products across four core businesses: cell therapies (including iNKT and Gamma Delta T Cells) for anti-cancer and anti-aging indications, novel anti-cancer drugs (PENAO, small nucleic acid drugs for liver cirrhosis), in vitro diagnostic kits for infectious diseases (SARS-CoV-2 antibody and antigen tests, CII-ArboViroPlex assay), and a consumer e-commerce platform selling probiotic health products such as the Beilemei brand. It also provides nucleic acid drug CRO services to pharmaceutical and biotechnology partners.
Product overview
Beroni Group is an international biopharmaceutical company with four core business areas: cell therapies, anti-cancer drug development, infectious disease diagnostics, and e-commerce health products. The company operates a diversified portfolio including commercial diagnostic products (SARS-CoV-2 test kits, CII-ArboViroPlex assay), pipeline therapeutics (PENAO anti-cancer drug in Phase 2 trials, iNKT cell therapy, small nucleic acid drugs for liver cirrhosis), consumer health products (Beilemei probiotic line), and technology platforms (AI-based drug R&D model, nanobody technology). The company provides nucleic acid drug CRO services through its Guangdong subsidiary and operates across Australia, China, Japan, and the USA.
Differentiator
Problem solved
Functional benefit
Brands
- PENAO: A targeted anti-cancer drug developed in collaboration with the University of New South Wales, led by Professor Philip Hogg. It is a First-in-Class anti-tumor compound containing active arsenic molecules that can cross the blood-brain barrier and is effective against all solid tumors.
- Beilemei (倍乐美)
- CII-ArboViroPlex
- SARS-CoV-2 IgG/IgM Antibody Detection Kit
- SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method)
Products and services
- Cell Therapies Anti-cancer and anti-aging cell therapy product line including Gamma Delta T Cells, DC-CIK immunotherapy, and NK/NKT cell therapies, delivered via the AABB-standard Cell Preparation Center in Zhuhai for clinical use.
- PENAO Anti-Cancer Drug
Companies that use Beroni Group
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Beroni Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature8 records
Beroni Group partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, minor and moderate.
- Tsinghua University School of SoftwarecoreCooperation agreement signed in 2024 to jointly develop AI-based drug R&D model. The model utilizes big data and machine learning for disease diagnosis and treatment solutions.
- Shenyang University of Chemical TechnologyminorPractice Base Agreement signed for cooperation in talent training, student internships, and potential scientific research collaboration.
- GenScript Biotech CorporationcoreCollaboration for development of a medical solution utilizing nanobody technology for COVID-19, particularly in conducting pseudovirus neutralization test, humanization and affinity maturation of nanobodies. Successfully completed SARS-CoV-2 pseudovirus neutralization assay in October 2020.
- Henan Linfeng Education FoundationminorStrategic agreement signed for cooperation in scientific research, achievement transformation, talents training and practicing fields.
- Beijing Health Industrial Investment Management Co., Ltd.moderateStrategic cooperation agreement signed to collaborate in fields of medical treatment, health care and aged care.
- Tianjin UniversitycoreCollaboration to develop novel solution for coronavirus (COVID-19). Discovered 24 types of nanobodies with high affinity to SARS-CoV-2 antigens in May 2020.
- Columbia UniversitycoreExclusive license for CII-ArboViroPlex rRT-PCR Assay developed by Columbia University. The assay can simultaneously test for Zika virus, all Dengue virus serotypes, Chikungunya virus, and West Nile virus.
- Beijing Higginger Pharmaceuticals Co., Ltd.minorBusiness discussion regarding Beroni Group's core projects including anti-cancer drug PENAO, ArboViroPlex rRT-PCR test kit, and SARS-CoV-2 IgG/IgM Antibody Detection Kit.
- University of New South Wales (UNSW)coreJoint R&D agreement for PENAO anti-cancer drug with Professor Philip Hogg, Director of the Roy Cancer Research Centre. Phase I clinical trial completed in Australia, Phase II clinical trial ongoing.
- China Three Gorges UniversitymoderateJoint R&D partnership for Aptamer-Wu coupled miR-23b-5p in anti-liver fibrosis applications.
- Tianjin Medical Industry Innovation Consortium (天津市生物医药学科创新联合体)moderateBeroni Tianjin as Vice Chairman unit, signed seed fund pool agreement to promote industry-academia-research cooperation in Tianjin's biomedical industry.
- BG HealthmoderateStrategic cooperation in medical and health-related fields.
Scale indicators4 records
Recent moves10 records
Expansion highlights5 records
Beroni Group competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
Beroni Group social profiles
Digital presenceBeroni Group compliance and trust
Trust signalCompliance5 records
Beroni Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Beroni Group leadership team
Management profileNumber of profiles
Profiles10 records
Beroni Group subsidiaries and ownership
Company hierarchySubsidiaries9 records
Beroni Group funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Beroni Group M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Beroni Group
What does Beroni Group do?
Beroni Group develops, manufactures, and commercializes biopharmaceutical products across four core businesses: cell therapies (including iNKT and Gamma Delta T Cells) for anti-cancer and anti-aging indications, novel anti-cancer drugs (PENAO, small nucleic acid drugs for liver cirrhosis), in vitro diagnostic kits for infectious diseases (SARS-CoV-2 antibody and antigen tests, CII-ArboViroPlex assay), and a consumer e-commerce platform selling probiotic health products such as the Beilemei brand. It also provides nucleic acid drug CRO services to pharmaceutical and biotechnology partners.
Is Beroni Group a public or private company?
Beroni Group is a public company. It is classified as public and is currently operating.
When was Beroni Group founded?
Beroni Group was founded in 2014. It employs 51 to 100 people.
Where is Beroni Group based?
Beroni Group is headquartered in Sydney, Australia, in the Oceania region.
How does Beroni Group make money?
Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are drug Commercialization, R&D Services and diagnostic Products.
Does Beroni Group have an API?
No public API is recorded for Beroni Group.
What industry is Beroni Group in?
Beroni Group's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of CRADAGAF, Probiotics & Digestive Health Supplements. Its NAICS code is 3254 and its SIC code is 2834.